ATA198998A - Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten - Google Patents

Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Info

Publication number
ATA198998A
ATA198998A AT0198998A AT198998A ATA198998A AT A198998 A ATA198998 A AT A198998A AT 0198998 A AT0198998 A AT 0198998A AT 198998 A AT198998 A AT 198998A AT A198998 A ATA198998 A AT A198998A
Authority
AT
Austria
Prior art keywords
vinyl
cefuroximaxetil
copolymerisate
pyrrolidone
preparation
Prior art date
Application number
AT0198998A
Other languages
English (en)
Other versions
AT413647B (de
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Priority to AT0198998A priority Critical patent/AT413647B/de
Priority to TW088120315A priority patent/TWI229603B/zh
Priority to AU16544/00A priority patent/AU759517B2/en
Priority to ES99959327T priority patent/ES2285866T3/es
Priority to PCT/EP1999/009096 priority patent/WO2000030647A1/en
Priority to CN99813759A priority patent/CN1330546A/zh
Priority to US09/445,741 priority patent/US6727243B1/en
Priority to DE69935609T priority patent/DE69935609T2/de
Priority to JP2000583530A priority patent/JP2002530338A/ja
Priority to IDW00200101088A priority patent/ID28615A/id
Priority to PL99348744A priority patent/PL348744A1/xx
Priority to SI9930969T priority patent/SI1133298T1/sl
Priority to BR9915694-6A priority patent/BR9915694A/pt
Priority to EP99959327A priority patent/EP1133298B1/de
Priority to NZ511588A priority patent/NZ511588A/en
Priority to AT99959327T priority patent/ATE357237T1/de
Priority to HU0104412A priority patent/HUP0104412A3/hu
Priority to KR1020017006542A priority patent/KR20010080566A/ko
Priority to YU34601A priority patent/YU34601A/sh
Priority to RU2001117518/15A priority patent/RU2248794C2/ru
Priority to IL14276299A priority patent/IL142762A0/xx
Priority to TR2001/01417T priority patent/TR200101417T2/xx
Priority to CA002348876A priority patent/CA2348876A1/en
Priority to CZ20011845A priority patent/CZ20011845A3/cs
Priority to SK716-2001A priority patent/SK7162001A3/sk
Priority to PE1999001186A priority patent/PE20001326A1/es
Priority to ARP990106024A priority patent/AR021405A1/es
Priority to MYPI99005158A priority patent/MY129564A/en
Priority to CO99074648A priority patent/CO5190668A1/es
Priority to ZA200103927A priority patent/ZA200103927B/en
Priority to NO20012526A priority patent/NO20012526L/no
Priority to AT0028104A priority patent/AT500135A1/de
Publication of ATA198998A publication Critical patent/ATA198998A/de
Application granted granted Critical
Publication of AT413647B publication Critical patent/AT413647B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
AT0198998A 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten AT413647B (de)

Priority Applications (32)

Application Number Priority Date Filing Date Title
AT0198998A AT413647B (de) 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
TW088120315A TWI229603B (en) 1998-11-26 1999-11-20 Beta-lactam compositions
YU34601A YU34601A (sh) 1998-11-26 1999-11-24 Kompozicije koje sadrže cefuroksim aksetil
PCT/EP1999/009096 WO2000030647A1 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil
CN99813759A CN1330546A (zh) 1998-11-26 1999-11-24 含有头孢呋肟酯的组合物
US09/445,741 US6727243B1 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil
DE69935609T DE69935609T2 (de) 1998-11-26 1999-11-24 Formulierungen enthaltend cefuroxim-axetil
JP2000583530A JP2002530338A (ja) 1998-11-26 1999-11-24 セフロキシムアクセチルを含む組成物
IDW00200101088A ID28615A (id) 1998-11-26 1999-11-24 Komposisi yang terdiri dari sefuroksim aksetil
PL99348744A PL348744A1 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil
SI9930969T SI1133298T1 (sl) 1998-11-26 1999-11-24 Sestavki, ki vključujejo cefuroksim aksetil
BR9915694-6A BR9915694A (pt) 1998-11-26 1999-11-24 Composições compreendendo cefuroxima axetil
EP99959327A EP1133298B1 (de) 1998-11-26 1999-11-24 Formulierungen enthaltend cefuroxim-axetil
NZ511588A NZ511588A (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil in a non gelatinous form when contacted with an aqueous liquid
AT99959327T ATE357237T1 (de) 1998-11-26 1999-11-24 Formulierungen enthaltend cefuroxim-axetil
HU0104412A HUP0104412A3 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil and process for their preparation
AU16544/00A AU759517B2 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil
IL14276299A IL142762A0 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil
ES99959327T ES2285866T3 (es) 1998-11-26 1999-11-24 Composiciones que comprenden cefuroxima axetil.
RU2001117518/15A RU2248794C2 (ru) 1998-11-26 1999-11-24 Комбинации, содержащие цефуроксимаксетил
TR2001/01417T TR200101417T2 (tr) 1998-11-26 1999-11-24 Sefuroksim aksetil içeren kompozisyonlar.
CA002348876A CA2348876A1 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil
CZ20011845A CZ20011845A3 (cs) 1998-11-26 1999-11-24 Farmaceutické přípravky obsahující cefuroximaxetil
SK716-2001A SK7162001A3 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil
KR1020017006542A KR20010080566A (ko) 1998-11-26 1999-11-24 세푸록심 악세틸을 포함하는 조성물
PE1999001186A PE20001326A1 (es) 1998-11-26 1999-11-25 Composicion farmaceutica que comprende cefuroxima-axetil, polimero y/o adsorbente
ARP990106024A AR021405A1 (es) 1998-11-26 1999-11-25 Composiciones de beta-lactama
MYPI99005158A MY129564A (en) 1998-11-26 1999-11-26 Compositions comprising cefuroxime axetil
CO99074648A CO5190668A1 (es) 1998-11-26 1999-11-26 Composiciones de beta lactama especificamente cefuroxima- axetil en una forma no gelatinosaal contacto con un liquido acuoso, util para la produccion de composiciones farmaceuticas que comprende cefuroxina-axetil como un ingrediente activo
ZA200103927A ZA200103927B (en) 1998-11-26 2001-05-15 Compositions comprising cefuroxime axetil.
NO20012526A NO20012526L (no) 1998-11-26 2001-05-23 Sammensetninger som innbefatter cefuroksimaksetil
AT0028104A AT500135A1 (de) 1998-11-26 2004-02-23 Organische verbindungen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0198998A AT413647B (de) 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Publications (2)

Publication Number Publication Date
ATA198998A true ATA198998A (de) 2005-09-15
AT413647B AT413647B (de) 2006-04-15

Family

ID=3525440

Family Applications (3)

Application Number Title Priority Date Filing Date
AT0198998A AT413647B (de) 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
AT99959327T ATE357237T1 (de) 1998-11-26 1999-11-24 Formulierungen enthaltend cefuroxim-axetil
AT0028104A AT500135A1 (de) 1998-11-26 2004-02-23 Organische verbindungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT99959327T ATE357237T1 (de) 1998-11-26 1999-11-24 Formulierungen enthaltend cefuroxim-axetil
AT0028104A AT500135A1 (de) 1998-11-26 2004-02-23 Organische verbindungen

Country Status (30)

Country Link
US (1) US6727243B1 (de)
EP (1) EP1133298B1 (de)
JP (1) JP2002530338A (de)
KR (1) KR20010080566A (de)
CN (1) CN1330546A (de)
AR (1) AR021405A1 (de)
AT (3) AT413647B (de)
AU (1) AU759517B2 (de)
BR (1) BR9915694A (de)
CA (1) CA2348876A1 (de)
CO (1) CO5190668A1 (de)
CZ (1) CZ20011845A3 (de)
DE (1) DE69935609T2 (de)
ES (1) ES2285866T3 (de)
HU (1) HUP0104412A3 (de)
ID (1) ID28615A (de)
IL (1) IL142762A0 (de)
MY (1) MY129564A (de)
NO (1) NO20012526L (de)
NZ (1) NZ511588A (de)
PE (1) PE20001326A1 (de)
PL (1) PL348744A1 (de)
RU (1) RU2248794C2 (de)
SI (1) SI1133298T1 (de)
SK (1) SK7162001A3 (de)
TR (1) TR200101417T2 (de)
TW (1) TWI229603B (de)
WO (1) WO2000030647A1 (de)
YU (1) YU34601A (de)
ZA (1) ZA200103927B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
EP1414417A4 (de) * 2000-12-01 2004-05-06 Abdul Rehman Khan Pharmazeutische formulierung
EP1911462A3 (de) * 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
US6524617B1 (en) * 2001-07-25 2003-02-25 Isp Investments Inc. Synergistic filler composition
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
ES2201932B2 (es) * 2001-11-23 2005-03-16 Glaxo Group Limited Composicion farmaceutica.
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
WO2004019901A2 (en) * 2002-08-30 2004-03-11 Orchid Chemicals & Pharmaceuticals Ltd. Sustained release pharmaceutical composition
WO2005002540A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Dry powder pharmaceutical suspension compositions of cefuroxime axetil
KR100552567B1 (ko) * 2003-08-23 2006-02-15 한국유나이티드제약 주식회사 수분 흡수에 안정하고 빠르게 붕해되는 세푸록심 악세틸을포함하는 정제의 조성물 및 제조 방법
EP2974718A1 (de) * 2005-04-29 2016-01-20 Cubist Pharmaceuticals, Inc. Therapeutische zusammensetzungen
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
US20130116239A1 (en) 2010-06-14 2013-05-09 ratiopharm GnbH Ivabradine-containing pharmaceutical composition with modified release
WO2014023710A1 (en) * 2012-08-07 2014-02-13 Sandoz Ag UNCOATED TABLET COMPRISING GRANULES INCLUDING A β-LACTAM ANTIBIOTIC AND HIGHLY DISPERSED SILICONE DIOXIDE
US9603804B2 (en) 2013-04-25 2017-03-28 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
WO2014174847A1 (ja) 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物
JP6018334B2 (ja) 2014-10-23 2016-11-02 杏林製薬株式会社 固形医薬組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
GB1572993A (en) * 1976-02-16 1980-08-13 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
IL85538A (en) * 1987-02-27 1991-09-16 Lilly Co Eli Sustained release matrix tablet formulations containing hydrophilic and enteric polymers
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3810343A1 (de) * 1988-03-26 1989-10-05 Basf Ag Verfahren zur herstellung von festen pharmazeutischen retardformen
DE4139963A1 (de) * 1991-12-04 1993-06-09 Basf Ag, 6700 Ludwigshafen, De Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung
DE19602757A1 (de) * 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US5663258A (en) * 1996-02-20 1997-09-02 Isp Investments Inc. Strongly swellable, moderately crosslinked copolymers of vinylpyrrolidone and vinyl acetate
DE19631085A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut
DE69730982T2 (de) * 1996-10-28 2005-09-01 General Mills, Inc., Minneapolis Einbettung und einkapselung von teilchen zur kontrollierten abgabe
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
CA2209868C (en) 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
EP1066040B1 (de) * 1998-03-03 2003-02-19 Daewoong Pharmaceutical Co., Ltd. Feuchtigkeitsstabile cefuroxim axetil enthaltende pharmazeutische zusammenstellungen
CA2239331C (en) 1998-05-29 1999-11-30 Bernard Charles Sherman Pharmaceutical tablets comprising cefuroxime axetil
DE19835823A1 (de) 1998-08-10 1999-10-07 Lindopharm Gmbh Pharmazeutische Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung sowie aus ihr hergestellte wässerige Suspension
KR100342943B1 (ko) 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
YU34601A (sh) 2004-09-03
NO20012526D0 (no) 2001-05-23
DE69935609D1 (de) 2007-05-03
ID28615A (id) 2001-06-21
CO5190668A1 (es) 2002-08-29
ES2285866T3 (es) 2007-11-16
KR20010080566A (ko) 2001-08-22
US6727243B1 (en) 2004-04-27
NO20012526L (no) 2001-05-23
CN1330546A (zh) 2002-01-09
MY129564A (en) 2007-04-30
SI1133298T1 (sl) 2007-10-31
CZ20011845A3 (cs) 2001-08-15
JP2002530338A (ja) 2002-09-17
BR9915694A (pt) 2001-08-14
AU759517B2 (en) 2003-04-17
DE69935609T2 (de) 2007-12-06
ATE357237T1 (de) 2007-04-15
AR021405A1 (es) 2002-07-17
TWI229603B (en) 2005-03-21
HUP0104412A3 (en) 2002-08-28
EP1133298A1 (de) 2001-09-19
SK7162001A3 (en) 2001-10-08
RU2248794C2 (ru) 2005-03-27
AT500135A1 (de) 2005-11-15
PE20001326A1 (es) 2000-12-12
HUP0104412A2 (hu) 2002-04-29
ZA200103927B (en) 2002-05-15
CA2348876A1 (en) 2000-06-02
IL142762A0 (en) 2002-03-10
TR200101417T2 (tr) 2001-11-21
EP1133298B1 (de) 2007-03-21
PL348744A1 (en) 2002-06-03
WO2000030647A1 (en) 2000-06-02
AU1654400A (en) 2000-06-13
AT413647B (de) 2006-04-15
NZ511588A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
ATA198998A (de) Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
ATE247099T1 (de) Sulfonamid-derivate, verfahren zur ihrer herstellung und ihre verwendung als arzneimittel
DE69935473D1 (de) Katalysator und dessen Verwendung in der Herstellung von Vinylacetat
DE60023023D1 (de) Zirkoniumdioxidsol und verfahren zu seiner herstellung
ATA102392A (de) Topisches terbinafinpräparat und verfahren zu seiner herstellung
DE69427117D1 (de) Organometall-Fluorenylverbindungen deren Herstellung und deren Verwendung
DE69527451D1 (de) Organometall-Fluorenylverbindungen, deren Herstellung und deren Verwendung
DE3751860D1 (de) Verwendung von spezifischem Kernmaterial und Schichten zur Herstellung pharmazeutischer Formulierungen, die stabil gegen die Verfärbung von Omeprazol sind
DE10299001I1 (de) Erythromycinderivate, ihre Verfahren zur Herstellung und ihre Verwendung als Arzneimittel.
ATE209878T1 (de) Interdentalreiniger und verfahren zu seiner herstellung
DE60109579D1 (de) Stabilisierte kieselsäure und verfahren zur herstellung und verwendung derselben
ATE208628T1 (de) Neue antithrombotische formulierung, verfahren zur herstellung und gebrauch davon
DE69501629D1 (de) Membranstruktur aus Keramik und Verfahren zu ihrer Herstellung
EP0811595A4 (de) Hydrochalconderivate, diese enthaltende kosmetische zubereitungen, und verfahren zur herstellung derselben
DE69514669D1 (de) Verbundstoffe aus microporösem film und vliesstoff
DE69819684D1 (de) Leicht zu öffnender beutel und vorrichtung zur herstellung desselben
NO944220D0 (no) Fremgangsmåte for fremstilling av katalysatorer for bruk i fremstillingen av vinylacetat
DE59706602D1 (de) 3-Hydroxy-Pyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE59905572D1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
DE69712610D1 (de) Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel
DE69711230D1 (de) Biologisch aktive substanzen, verfahren zur herstellung und sie enthaltende zusammensetzungen
DE69930512D1 (de) Verfahren zur herstellung von hexafluorpropen aus cc1f2cc1fcf3 und azeotrope von cc1f2cc1fcf3 mit hf
DE60218807D1 (de) Rutheniumkomplexe und deren Verwendung zur Herstellung von Alkoholen
DE69809284D1 (de) Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen
ATE332082T1 (de) Insektizide aerosol-zusammensetzung und insektizide zusammensetzung zu ihrer herstellung

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee